**Supplementary Table S1.** Age-sex adjusted baseline factors related to the development of post-COVID-19 syndrome in primary SS patients.

	Post-COVID-19 syndrome (n = 38)	Recovered patients (n = 57)	P-value	Unadjusted OR [95%CI]	Adjusted OR [95%CI]†
Age, years (mean, range)	54.3 ± 13.3	56.6 ± 14.9	0.443	0.99 [0.96-1.02]	0.99 [0.96-1.02]
Sex, male	2 (5.3)	3 (5.3)	1.000	1.00 [0.13-6.32]	1.10 [0.14-7.17]
Continent, Europe	34 (89.5)	45 (78.9)	0.288	2.27 [0.72-8.67]	2.43 [0.76-9.40]
Comorbidities					
Cardiovascular disease	5 (13.2)	7 (12.3)	1.000	1.08 [0.30-3.68]	1.29 [0.33-4.86]
Pulmonary disease	7 (18.4)	10 (17.5)	1.000	1.06 [0.35-3.06]	1.20 [0.38-3.65]
Smoking (past/active)	7 (18.4)	11 (19.3)	1.000	0.94 [0.32-2.67]	0.98 [0.31-2.87]
Hypertension	11 (28.9)	15 (26.3)	0.963	1.14 [0.45-2.84]	1.36 [0.49-3.73]
Diabetes Mellitus	4 (10.5)	3 (5.3)	0.575	2.12 [0.44-11.31]	2.70 [0.52-15.53]
Obesity	6 (15.8)	5 (8.8)	0.472	1.95 [0.54-7.27]	1.94 [0.54-7.28]
Cancer history	2 (5.3)	4 (7.0)	1.000	0.74 [0.10-3.98]	0.87 [0.11-5.10]
Renal failure	0 (0)	0 (0)	1.000	–	
COVID diagnosis confirmation			0.481		
PCR+	27 (71.1)	46 (80.7)		REF	REF
Serology+	3 (7.9)	2 (3.5)		2.56 [0.4-20.34]	2.48 [0.38-19.87]
Not tested	8 (21.1)	9 (15.8)		1.51 [0.51-4.43]	1.66 [0.55-5.00]
Fever (≥ 38ºC)	15/28 (53.6)	22/35 (62.9)	0.627	0.68 [0.25-1.87]	0.71 [0.25-2.04]
Respiratory rate (≥ 20BPM)	10/17 (58.8)	10/23 (43.5)	0.522	1.86 [0.53-6.84]	2.23 [0.59-9.34]
Baseline O2 saturation (%)					
≤95%	12/27 (44.4)	7/32 (21.9)	0.117	2.86 [0.94-9.24]	3.00 [0.97-10.04]
≤90%	6/27 (22.2)	2/32 (6.2)	0.160	4.29 [0.89-31.25]	5.03 [0.99-38.59]
Radiological features, pulmonary infiltrate	18/23 (78.3)	15/28 (53.6)	0.123	3.12 [0.94-11.62]	5.07 [1.34-23.31]
Laboratory parameters					
Anemia	4/24 (16.7)	3/23 (13)	1.000	1.33 [0.26-7.50]	1.95 [0.33-13.23]
Thrombocytopenia	2/24 (8.3)	1/23 (4.3)	1.000	2.00 [0.18-44.9]	2.71 [0.22-66.76]
Leukopenia	2/24 (8.3)	2/23 (8.7)	1.000	0.95 [0.11-8.55]	0.96 [0.11-8.78]
Lymphopenia	15/23 (65.2)	10/23 (43.5)	0.236	2.44 [0.75-8.31]	2.52 [0.77-8.75]
Raised D Dimer levels	12/19 (63.2)	9/16 (56.2)	0.945	1.33 [0.34-5.30]	2.03 [0.4-11.69]
Raised LDH levels	15/21 (71.4)	5/16 (31.2)	0.036	5.50 [1.40-24.74]	10.36 [1.97-79.56]
Raised ferritin levels	6/14 (42.9)	3/11 (27.3)	0.699	2.00 [0.38-12.26]	1.85 [0.32-11.98]
Raised liver enzymes levels	6/24 (25.0)	2/19 (10.5)	0.414	2.83 [0.56-21.20]	2.98 [0.58-22.68]
Raised CRP levels	20/22 (90.9)	14/23 (60.9)	0.046	6.43 [1.40-46.61]	7.33 [1.52-56.82]
COVID-19 treatment					
Hydroxychloroquine	25 (65.8)	20 (35.1)	0.006	3.56 [1.53-8.64]	3.51 [1.50-8.55]
Azithromycin	9 (23.7)	10 (17.5)	0.637	1.46 [0.52-4.04]	1.54 [0.54-4.36]
Oral prednisone	9 (23.7)	13 (22.8)	1.000	1.05 [0.39-2.76]	1.05 [0.39-2.78]
Intravenous methylprednisolone	3 (7.9)	0 (0)	0.120	–	
Antiviral agents	14 (36.8)	9 (15.8)	0.036	3.11 [1.20-8.47]	3.38 [1.26-9.65]
Tocilizumab	1 (2.6)	1 (1.8)	1.000	1.51 [0.06-39.07]	1.84 [0.06-53.60]
Management, hospital admission	17 (44.7)	8 (14.0)	0.002	4.96 [1.91-13.87]	8.29 [2.74-29.21]
Hospital discharge days after covid dx (mean ± SD)	5.3 ± 8.8	1.7 ± 5.7	0.031	1.08 [1.01-1.17]	1.10 [1.03-1.20]
Complications during admision					
Supplemental oxygen	11 (28.9)	4 (7.0)	0.010	5.40 [1.67-20.96]	6.94 [2.03-29.02]

REF: reference value.

†Logistic multivariate regression models adjusting for age and sex.

Supplementary Fig. S1. Flow chart summarising the follow-up of SS patients according to their symptomatic status, follow-up status and the fulfilment the NICE definition for ongoing symptomatic COVID-19 and post-COVID-19 syndrome.

Supplementary Table S2. SS-related features associated with post-COVID-19 syndrome.

	Post-COVID-19 syndrome (n = 38)	Recovered patients (n = 57)	P-value	Unadjusted OR [95%CI]	Adjusted OR [95%CI][†]
Sjögren criteria					
Dry eye	37 (97.4)	54 (94.7)	0.917	2.06 [0.25-42.43]	2.46 [0.28-52.90]
Dry mouth	36 (94.7)	51 (89.5)	0.598	2.12 [0.46-15.02]	2.81 [0.53-22.08]
Positive ocular tests 2016	25/31 (80.6)	36/46 (78.3)	1.000	1.16 [0.38-3.78]	1.52 [0.41-6.53]
Positive oral tests 2016	9/14 (64.3)	23/34 (67.6)	1.000	0.86 [0.24-3.36]	1.19 [0.27-5.91]
Salivary bx	27/30 (90.0)	30/36 (83.3)	0.670	1.80 [0.43-9.19]	2.75 [0.53-18.69]
Ro antibodies	27/36 (75.0)	48 (84.2)	0.409	0.56 [0.20-1.60]	0.44 [0.13-1.40]
La antibodies	12/35 (34.3)	27/55 (49.1)	0.245	0.54 [0.22-1.28]	0.52 [0.20-1.36]
Baseline SjS-related therapies					
Any	25 (65.8)	30 (52.6)	0.289	1.73 [0.75-4.12]	1.50 [0.59-3.88]
Hydroxychloroquine	20 (52.6)	18 (31.6)	0.054	2.41 [1.04-5.69]	2.13 [0.84-5.52]
Corticosteroids	8 (21.1)	14 (24.6)	0.882	0.82 [0.29-2.16]	0.68 [0.21-1.99]
Immunosuppressants	7 (18.4)	12 (21.1)	0.958	0.85 [0.29-2.35]	0.63 [0.18-1.98]
Biological therapies	2 (5.3)	4 (7.0)	1.000	0.74 [0.10-3.98]	0.81 [0.10-4.59]

[†]Logistic multivariate regression models adjusting for age, sex and hospital admission